Most Comprehensive and Curated Database of References Related to Rare Diseases

The innovators globally are continuously working to develop the drugs and therapies for the treatment and diagnosis of Rare Diseases. Some Positives:

Our Motto

Contributing its part in the development of technologies for Diagnosis and Treatment of Rare Diseases by helping innovators of companies, research institutes, to access the already available information for rare diseases, so that the innovators have information readily available for their use with respect to current technologies in the domain and therefore a better Return on Investment is achieved  for the overall development of drug/ treatment/ and technology for diagnosis. The information would help innovators to innovate with confidence, and convert emerging opportunities into market leading products

Salient Features

How this Helps

Through this database, we are supporting the innovators and decision makers at various levels, by providing them access to filtered information related to different technologies developed and/or are under development, which is useful for them to save their resources, and spend the grant money majorly on development of technologies (without re-inventing the wheel) rather than on collecting the data of already published technologies.

Pricing

Basic

Premium

Filtered Dataset - as a complete list

First Level Division of Patents

Patents further filtered based on technical heads

-

Basic Visualizations - Filing Trend, Top Assignee, Major Geographies, Division of patents based on first level

Extensive Graphs based on further technical analysis

-

Access to one detailed report per year

-

Available as an Add-on

Free 10 Hours discussion with our analysts

-

Estimated Subscription Cost (per user)

US $1,699 per year

US $2,499 per year

Pricing

Basic

Estimated Subscription Cost (per user): US $1,699 per year

Premium

Estimated Subscription Cost (per user): US $2,499 per year

Interested? Request a Demo/ Trial

  • Hidden
  • This field is for validation purposes and should be left unchanged.
Scroll to Top